Microbiology & Immunology

Recent Publications

• A Serum-Induced Transcriptome and Serum Cytokine Signature Obtained at Diagnosis Correlates with the Development of Early Pancreatic Ductal Adenocarcinoma Metastasis.

  (Tsai S, McOlash L, Jia S, Zhang J, Simpson P, Kaldunski ML, Aldakkak M, Grewal J, Palen K, Dwinell MB, Johnson BD, Mackinnon A, Hessner MJ, Gershan JA.) Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):680-689.

• Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation.

  (Boyle KA, Van Wickle J, Hill RB, Marchese A, Kalyanaraman B, Dwinell MB.) J Biol Chem. 2018 09 21;293(38):14891-14904.

• Corrigendum to 'A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds' [REDOX 14C (2017) 316-327].

  (Kalyanaraman B, Cheng G, Hardy M, Ouari O, Lopez M, Joseph J, Zielonka J, Dwinell MB.) Redox Biol. 2018 06;16:426-427.

• Diacylglycerol kinase ζ (DGKζ) and Casitas b-lineage proto-oncogene b-deficient mice have similar functional outcomes in T cells but DGKζ-deficient mice have increased T cell activation and tumor clearance.

  (Wesley EM, Xin G, McAllister D, Malarkannan S, Newman DK, Dwinell MB, Cui W, Johnson BD, Riese MJ.) Immunohorizons. 2018 Apr 01;2(4):107-118.

• A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds.

  (Kalyanaraman B, Cheng G, Hardy M, Ouari O, Lopez M, Joseph J, Zielonka J, Dwinell MB.) Redox Biol. 2018 04;14:316-327.

• Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models.

  (Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, Dwinell MB, Hunt B, Evans DB, Gershan J, James MA.) BMC Cancer. 2018 03 27;18(1):335.

• GEMMs Are a Gem When it Comes to Defining the Role of HIF2α in Mucinous Cystic Neoplasms.

  (Boyle KA, Dwinell MB.) Cell Mol Gastroenterol Hepatol. 2018;5(2):165-166.

• Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, Antiproliferative Effects and Future EPR Studies.

  (Kalyanaraman B, Cheng G, Hardy M, Ouari O, Sikora A, Zielonka J, Dwinell MB.) Cell Biochem Biophys. 2017 Dec;75(3-4):311-317.

• Differences in Sulfotyrosine Binding amongst CXCR1 and CXCR2 Chemokine Ligands.

  (Moussouras NA, Getschman AE, Lackner ER, Veldkamp CT, Dwinell MB, Volkman BF.) Int J Mol Sci. 2017 Sep 03;18(9).

• CCR7 Sulfotyrosine Enhances CCL21 Binding.

  (Phillips AJ, Taleski D, Koplinski CA, Getschman AE, Moussouras NA, Richard AM, Peterson FC, Dwinell MB, Volkman BF, Payne RJ, Veldkamp CT.) Int J Mol Sci. 2017 Aug 25;18(9).

• Mitochondria-targeted metformins: anti-tumour and redox signalling mechanisms.

  (Kalyanaraman B, Cheng G, Hardy M, Ouari O, Sikora A, Zielonka J, Dwinell M.) Interface Focus. 2017 Apr 06;7(2):20160109.

• Structural basis for chemokine recognition by a G protein-coupled receptor and implications for receptor activation.

  (Ziarek JJ, Kleist AB, London N, Raveh B, Montpas N, Bonneterre J, St-Onge G, DiCosmo-Ponticello CJ, Koplinski CA, Roy I, Stephens B, Thelen S, Veldkamp CT, Coffman FD, Cohen MC, Dwinell MB, Thelen M, Peterson FC, Heveker N, Volkman BF.) Sci Signal. 2017 Mar 21;10(471).

• Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma.

  (Roy I, Boyle KA, Vonderhaar EP, Zimmerman NP, Gorse E, Mackinnon AC, Hwang RF, Franco-Barraza J, Cukierman E, Tsai S, Evans DB, Dwinell MB.) Lab Invest. 2017 03;97(3):302-317.

• Exploiting agonist biased signaling of chemokines to target cancer.

  (Roy I, Getschman AE, Volkman BF, Dwinell MB.) Mol Carcinog. 2017 03;56(3):804-813.

• E-cadherin re-expression shows in vivo evidence for mesenchymal to epithelial transition in clonal metastatic breast tumor cells.

  (Palen K, Weber J, Dwinell MB, Johnson BD, Ramchandran R, Gershan JA.) Oncotarget. 2016 Jul 12;7(28):43363-43375.